Seyffert J, Steffes W. Vitiligo following alemtuzumab therapy in multiple sclerosis: a demonstration of secondary autoimmunity. Int J Res Dermatol [Internet]. 2019 Oct. 21 [cited 2026 Feb. 19];5(4):882-4. Available from: https://www.ijord.com/index.php/ijord/article/view/777